Tinidazole
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tinidazole: From Protozoal and Anaerobic Infections to Postmenopausal Atrophic Vaginitis
One-Sentence Summary
Tinidazole is a nitroimidazole antimicrobial internationally used for protozoal and anaerobic bacterial infections (e.g. trichomoniasis, giardiasis, amoebiasis); it currently holds no marketing authorisation in the UK dataset reviewed here. The TxGNN model predicts a possible role in postmenopausal atrophic vaginitis, but this specific link is currently supported by zero clinical trials and zero publications, and the underlying rationale itself flags the connection as biologically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the Evidence Pack; internationally recognised for protozoal infections (trichomoniasis, giardiasis, amoebiasis) and anaerobic bacterial infections |
| Predicted New Indication | Postmenopausal Atrophic Vaginitis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Tinidazole is not available. Based on general pharmacological knowledge, Tinidazole belongs to the 5-nitroimidazole class, which acts by disrupting DNA synthesis in anaerobic bacteria and protozoa (a mechanism analogous to metronidazole). Its established efficacy is in infections such as trichomoniasis, giardiasis and amoebiasis, and it is not known to have any hormonal or anti-inflammatory activity.
Postmenopausal atrophic vaginitis, by contrast, is caused by oestrogen deficiency leading to vaginal mucosal thinning — it is a non-infectious, hormone-driven condition. There is no known pharmacological pathway by which an antiprotozoal/antianaerobic agent would address this pathology.
The Evidence Pack’s own repurposing rationale for this candidate explicitly notes that the predicted link most likely reflects a shared anatomical node (“vagina”) within the knowledge graph rather than a genuine mechanistic relationship, and states there is “no direct connection” and “a lack of biological plausibility.” This should be treated as a low-confidence, graph-proximity artefact rather than a genuine repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No marketing authorisation is currently on record for Tinidazole in the UK regulatory data reviewed for this Evidence Pack (0 licences; market status: not marketed).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a numerically high TxGNN similarity score, this candidate has no supporting clinical trial or literature evidence, and the documented mechanistic rationale itself identifies the prediction as a likely knowledge-graph co-location artefact rather than a genuine pharmacological signal. Combined with the absence of any UK marketing authorisation for Tinidazole, this indication does not warrant further investment at this time.
To proceed, the following is needed:
- Confirmation of Tinidazole’s mechanism of action (MOA) from DrugBank or SmPC sources
- A targeted literature/trial search specific to “tinidazole AND atrophic vaginitis” to rule out any signal missed by automated evidence collection
- UK safety data (key warnings, contraindications, DDIs) from the MHRA-approved SmPC, as none is currently available
- A regulatory pathway assessment, given Tinidazole currently has zero marketing authorisations in the UK
Additional observation (for prioritisation, not part of this candidate’s evaluation): Among the ten TxGNN-ranked indications in this Evidence Pack, rank 5 (“AIDS”) has materially stronger support — one registered clinical trial (NCT03412071) and 17 literature records, largely relating to Tinidazole’s established role in treating opportunistic protozoal co-infections (e.g. amoebiasis, trichomoniasis) in HIV/AIDS patients (evidence level L3, decision stage S1). If the team wishes to pursue a more evidence-backed repurposing direction for this drug, that candidate would be a more productive starting point for a separate evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.